BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 19451405)

  • 1. Impact of calcineurin inhibitors on urinary excretion of mycophenolic acid and its glucuronide in kidney transplant recipients.
    Naito T; Mino Y; Otsuka A; Ushiyama T; Ito T; Ozono S; Kagawa Y; Kawakami J
    J Clin Pharmacol; 2009 Jun; 49(6):710-8. PubMed ID: 19451405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclosporine alters correlation between free and total mycophenolic acid in kidney transplant recipients in the initial phase.
    Mino Y; Naito T; Otsuka A; Takayama T; Ozono S; Kagawa Y; Kawakami J
    J Clin Pharm Ther; 2011 Apr; 36(2):217-24. PubMed ID: 21366651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients.
    Ting LS; Partovi N; Levy RD; Riggs KW; Ensom MH
    Ther Drug Monit; 2008 Jun; 30(3):282-91. PubMed ID: 18520599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation.
    Mino Y; Naito T; Matsushita T; Otsuka A; Ushiyama T; Ozono S; Hishida A; Kagawa Y; Kawakami J
    Ther Drug Monit; 2008 Dec; 30(6):656-61. PubMed ID: 18978521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable lung transplant recipients.
    Ting LS; Partovi N; Levy RD; Riggs KW; Ensom MH
    Ann Pharmacother; 2006 Sep; 40(9):1509-16. PubMed ID: 16882870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism.
    van Agteren M; Armstrong VW; van Schaik RH; de Fijter H; Hartmann A; Zeier M; Budde K; Kuypers D; Pisarski P; Le Meur Y; van der Werf M; Mamelok RD; Oellerich M; van Gelder T
    Ther Drug Monit; 2008 Aug; 30(4):439-44. PubMed ID: 18641546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.
    de Winter BC; van Gelder T; Sombogaard F; Shaw LM; van Hest RM; Mathot RA
    J Pharmacokinet Pharmacodyn; 2009 Dec; 36(6):541-64. PubMed ID: 19904584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concentrations of mycophenolic acid and glucuronide metabolites under concomitant therapy with cyclosporine or tacrolimus.
    Patel CG; Harmon M; Gohh RY; Akhlaghi F
    Ther Drug Monit; 2007 Feb; 29(1):87-95. PubMed ID: 17304155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil.
    Jain AB; Hamad I; Zuckerman S; Zhang S; Warty VS; Fung JJ; Venkataramanan R
    Liver Transpl Surg; 1999 Mar; 5(2):101-6. PubMed ID: 10071348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation.
    Naito T; Shinno K; Maeda T; Kagawa Y; Hashimoto H; Otsuka A; Takayama T; Ushiyama T; Suzuki K; Ozono S
    Biol Pharm Bull; 2006 Feb; 29(2):275-80. PubMed ID: 16462031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporine concentration-dependent increase in concentration ratio of mycophenolic acid acyl and phenol glucuronides to mycophenolic acid in stable kidney transplant recipients.
    Mino Y; Naito T; Otsuka A; Ushiyama T; Ozono S; Kagawa Y; Kawakami J
    Clin Biochem; 2009 May; 42(7-8):595-601. PubMed ID: 19100248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of metal cations on plasma trough concentration of mycophenolic Acid and its glucuronide in tacrolimus-treated and cyclosporine-treated kidney transplant recipients.
    Naito T; Mino Y; Otsuka A; Ushiyama T; Ozono S; Kagawa Y; Kawakami J
    Biol Pharm Bull; 2008 Jun; 31(6):1292-6. PubMed ID: 18520072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
    Tedesco-Silva H; Felipe CR; Slade A; Schmouder RL; Medina Pestana JO
    Ther Drug Monit; 2012 Dec; 34(6):652-9. PubMed ID: 23131696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of MPA and MPAG removal by continuous venovenous hemodiafiltration and continuous venovenous hemofiltration.
    Cussonneau X; Bolon-Larger M; Prunet-Spano C; Bastien O; Boulieu R
    Ther Drug Monit; 2008 Feb; 30(1):100-2. PubMed ID: 18223470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of pharmacokinetics of mycophenolic acid and its metabolites between living donor liver transplant recipients and deceased donor liver transplant recipients.
    Shen B; Chen B; Zhang W; Mao H; Shen C; Deng X; Zhan X; Chen H
    Liver Transpl; 2009 Nov; 15(11):1473-80. PubMed ID: 19877254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolic acid clinical pharmacokinetics influenced by a cyclosporine C2 based immunosuppressive regimen in renal allograft recipients.
    Mandla R; Midtvedt K; Line PD; Hartmann A; Bergan S
    Transpl Int; 2006 Jan; 19(1):44-53. PubMed ID: 16359376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication.
    Brown NW; Aw MM; Mieli-Vergani G; Dhawan A; Tredger JM
    Ther Drug Monit; 2002 Oct; 24(5):598-606. PubMed ID: 12352931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
    Beckebaum S; Armstrong VW; Cicinnati VR; Streit F; Klein CG; Gerken G; Paul A; Oellerich M
    Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients.
    Ettenger R; Bartosh S; Choi L; Zhu W; Niederberger W; Campestrini J; Bastien MC; Schmouder R
    Pediatr Transplant; 2005 Dec; 9(6):780-7. PubMed ID: 16269051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.